Get started
Author

Luc Friboulet

Observed names: Friboulet, Luc, L Friboulet, L. Friboulet
Observed institutions: Université Paris-Sud, Broad Institute, Centre National de la Recherche Scientifique, Harvard University, Inserm, Université Paris-Saclay, Institut Gustave Roussy, Massachusetts General Hospital, Institute Mutualiste Montsouris, The Cancer Institute Hospital, Japanese Foundation For Cancer Research, Prédicteurs moléculaires et nouvelles cibles en oncologie, Aspects métaboliques et systémiques de l'oncogénèse pour de nouvelles approches thérapeutiques, Fondation Gustave Roussy, Massachusetts Institute of Technology, KTH Royal Institute of Technology
ORCID: 0000-0002-1129-4978
Observed ORCID: 0000-0002-1129-4978
OpenAlex ID: A5025583232
Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK -Rearranged Lung Cancer
2016 · Justin F. Gainor, Leila Dardaei, et al. · Cancer Discovery · 1,172
The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non–Small Cell Lung Cancer
2014 · Luc Friboulet, Nanxin Li, et al. · Cancer Discovery · 863
PDF
Patient-derived models of acquired resistance can identify effective drug combinations for cancer
2014 · Adam S. Crystal, Alice T. Shaw, et al. · Science · 724
Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F
2015 · Alice T. Shaw, Luc Friboulet, et al. · New England Journal of Medicine · 498
PDF
PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models
2015 · Helen Y. Zou, Luc Friboulet, et al. · Cancer Cell · 483
PDF
Acquired Resistance to Crizotinib from a Mutation in CD74 – ROS1
2013 · Mark M. Awad, Ryohei Katayama, et al. · New England Journal of Medicine · 425
PDF
ERCC1 Isoform Expression and DNA Repair in Non–Small-Cell Lung Cancer
2013 · Luc Friboulet, Ken André Olaussen, et al. · New England Journal of Medicine · 381
PDF
Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive Lung Cancer
2018 · Satoshi Yoda, Jessica J. Lin, et al. · Cancer Discovery · 331
Making the first move in EGFR-driven or ALK-driven NSCLC: first-generation or next-generation TKI?
2018 · Gonzalo Recondo, Francesco Facchinetti, et al. · Nature Reviews Clinical Oncology · 326
Two Novel ALK Mutations Mediate Acquired Resistance to the Next-Generation ALK Inhibitor Alectinib
2014 · Ryohei Katayama, Luc Friboulet, et al. · Clinical Cancer Research · 295
Clinicogenomic Analysis of FGFR2 -Rearranged Cholangiocarcinoma Identifies Correlates of Response and Mechanisms of Resistance to Pemigatinib
2020 · Ian M. Silverman, Antoine Hollebecque, et al. · Cancer Discovery · 293
PDF
Patterns of Metastatic Spread and Mechanisms of Resistance to Crizotinib in ROS1-Positive Non–Small-Cell Lung Cancer
2017 · Justin F. Gainor, Diane Tseng, et al. · JCO Precision Oncology · 271
Secreted PD-L1 variants mediate resistance to PD-L1 blockade therapy in non–small cell lung cancer
2019 · Bo Gong, Kazuma Kiyotani, et al. · The Journal of Experimental Medicine · 248
Cabozantinib Overcomes Crizotinib Resistance in ROS1 Fusion–Positive Cancer
2014 · Ryohei Katayama, Yuka Kobayashi, et al. · Clinical Cancer Research · 205
SHP2 inhibition restores sensitivity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitors
2018 · Leila Dardaei, Hui Qin Wang, et al. · Nature Medicine · 200
Molecular mechanisms of resistance to first- and second-generation ALK inhibitors in ALK-rearranged lung cancer
2016 · J. Gainor, L. Dardaei, et al. · European Journal of Cancer · 199
Primary Patient-Derived Cancer Cells and Their Potential for Personalized Cancer Patient Care
2017 · David P. Kodack, Anna F. Farago, et al. · Cell Reports · 196
PDF
Progression-Free and Overall Survival in ALK-Positive NSCLC Patients Treated with Sequential Crizotinib and Ceritinib
2015 · Justin F. Gainor, Daniel S.W. Tan, et al. · Clinical Cancer Research · 182
BRAF in non-small cell lung cancer (NSCLC): Pickaxing another brick in the wall
2018 · Alessandro Leonetti, Francesco Facchinetti, et al. · Cancer Treatment Reviews · 179
Diverse Resistance Mechanisms to the Third-Generation ALK Inhibitor Lorlatinib in ALK-Rearranged Lung Cancer
2019 · Gonzalo Recondo, Laura Mezquita, et al. · Clinical Cancer Research · 174
Molecular mechanisms of acquired resistance to third-generation EGFR-TKIs in EGFR T790M-mutant lung cancer
2017 · C. Ricordel, L. Friboulet, et al. · Annals of Oncology · 156
The clinical landscape of cell-free DNA alterations in 1671 patients with advanced biliary tract cancer
2022 · J.E. Berchuck, F. Facchinetti, et al. · Annals of Oncology · 152
Crizotinib-Resistant ROS1 Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for ROS1 - and ALK -Rearranged Lung Cancers
2016 · Francesco Facchinetti, Yohann Loriot, et al. · Clinical Cancer Research · 151
P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer
2015 · Ryohei Katayama, Takuya Sakashita, et al. · EBioMedicine · 144
PDF
Acquired Resistance Mutations to ALK Inhibitors Identified by Single Circulating Tumor Cell Sequencing in ALK -Rearranged Non–Small-Cell Lung Cancer
2019 · Emma Pailler, Vincent Faugeroux, et al. · Clinical Cancer Research · 124
Works count: 469
Citation count: 10,440
H-index: 45
I10-index: 66
Year
Topic
Type